MARKET

BLUE

BLUE

bluebird bio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

18.32
+0.64
+3.62%
After Hours: 17.90 -0.42 -2.29% 18:08 09/17 EDT
OPEN
17.68
PREV CLOSE
17.68
HIGH
18.43
LOW
17.42
VOLUME
2.65M
TURNOVER
--
52 WEEK HIGH
59.32
52 WEEK LOW
17.14
MARKET CAP
1.24B
P/E (TTM)
-1.4536
1D
5D
1M
3M
1Y
5Y
Sickle Cell Disease Drugs Market: Industry Outlook, Classification, Demand, Regional Analysis and Forecast to 2030
Research Nester released a report titled which delivers a detailed overview of the global sickle cell disease drugs market in terms of market segmentation by treatment type, disease type, end-user, and by region.
AmericaNewsHour · 2d ago
2seventy bio Announces Upcoming Investor Events
CAMBRIDGE, Mass., September 13, 2021--2seventy bio, the planned oncology spin-off of bluebird bio (NASDAQ: BLUE) announced today that it will host a series of investor events to share further detail on its research pipeline and strategy.
Business Wire · 5d ago
7 Busted Biotech Stocks Due for a Rebound
Investor Place · 09/08 16:25
Why Is Bluebird (BLUE) Down 13.3% Since Last Earnings Report?
Zacks.com · 09/08 15:30
BRIEF-Bluebird Bio Secures $75 Million In Private Placement Equity Financing
reuters.com · 09/08 11:37
bluebird bio Secures $75 Million Private Placement
MT Newswires · 09/08 08:34
BRIEF-Bluebird Bio Announces Key Management And Board Appointments And Upcoming Investor Events
reuters.com · 09/07 20:44
bluebird bio Announces Key Management and Board Appointments and Upcoming Investor Events
--Marcela Maus named to bluebird bio board of directors
Business Wire · 09/07 20:05
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BLUE. Analyze the recent business situations of bluebird bio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 20 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BLUE stock price target is 24.53 with a high estimate of 45.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 389
Institutional Holdings: 55.56M
% Owned: 82.22%
Shares Outstanding: 67.58M
TypeInstitutionsShares
Increased
84
8.39M
New
40
947.90K
Decreased
60
5.99M
Sold Out
44
2.74M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Non-Executive Chairman/Independent Director
Daniel Lynch
President/Chief Executive Officer/Director
Nick Leschly
Chief Financial Officer/Chief Accounting Officer
William Baird
Chief Operating Officer/Secretary
Jason Cole
Chief Scientific Officer
Philip Gregory
Other
Thomas Klima
Director
Marcela Maus
Independent Director
John Agwunobi
Independent Director
Wendy Dixon
Independent Director
Ramy Ibrahim
Independent Director
William Sellers
Independent Director
Denice Torres
Independent Director
Mark Vachon
No Data
About BLUE
bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

Webull offers kinds of bluebird bio Inc stock information, including NASDAQ:BLUE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLUE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BLUE stock methods without spending real money on the virtual paper trading platform.